Technical Analysis for INCY - Incyte Corporation
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Historical INCY trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Inside Day | Range Contraction | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Multiple of Ten Bearish | Other | 0.27% | |
Oversold Stochastic | Weakness | 0.27% | |
Slingshot Bearish | Bearish Swing Setup | -2.42% | |
Stochastic Buy Signal | Bullish | -2.42% | |
Multiple of Ten Bullish | Other | -2.42% | |
Oversold Stochastic | Weakness | -2.42% | |
Lizard Bullish | Bullish Day Trade Setup | -0.46% | |
Doji - Bullish? | Reversal | -0.46% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
Alert | Time | |
---|---|---|
60 Minute Opening Range Breakdown | about 19 hours ago | |
Up 1% | about 19 hours ago | |
Trending on StockTwits | 1 day ago | |
Down 3% | 1 day ago | |
60 Minute Opening Range Breakdown | 2 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 02/11/2021
Incyte Corporation Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Solid Tumors Chemical Compounds Organic Compounds Inflammation Wilmington Psoriasis Pancreatic Cancer Hematologic Malignancies Janus Diabetic Nephropathy Clinical Trial Product Myelofibrosis Janus Kinase Inhibitor Clinical Trial Products Morpholines Nitriles Polycythemia
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 110.365 |
52 Week Low | 62.51 |
Average Volume | 1,138,974 |
200-Day Moving Average | 92.19 |
50-Day Moving Average | 88.45 |
20-Day Moving Average | 85.40 |
10-Day Moving Average | 80.90 |
Average True Range | 3.04 |
ADX | 24.24 |
+DI | 16.65 |
-DI | 31.90 |
Chandelier Exit (Long, 3 ATRs ) | 89.04 |
Chandelier Exit (Short, 3 ATRs ) | 85.82 |
Upper Bollinger Band | 95.57 |
Lower Bollinger Band | 75.23 |
Percent B (%b) | 0.17 |
BandWidth | 23.82 |
MACD Line | -3.20 |
MACD Signal Line | -2.38 |
MACD Histogram | -0.8185 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 81.47 | ||||
Resistance 3 (R3) | 81.48 | 80.56 | 81.00 | ||
Resistance 2 (R2) | 80.56 | 79.85 | 80.55 | 80.84 | |
Resistance 1 (R1) | 79.61 | 79.40 | 79.15 | 79.60 | 80.69 |
Pivot Point | 78.69 | 78.69 | 78.46 | 78.68 | 78.69 |
Support 1 (S1) | 77.74 | 77.98 | 77.28 | 77.73 | 76.63 |
Support 2 (S2) | 76.82 | 77.53 | 76.81 | 76.48 | |
Support 3 (S3) | 75.87 | 76.82 | 76.32 | ||
Support 4 (S4) | 75.86 |